

Princess Margaret Hematology Conference (PMHC)
March 26-28, 2026
Courtyard Marriott Downtown Hotel
Draft Program – January 19, 2026

Thursday March 26, 2026

8:00-9:00

Registration and Breakfast

9:00-9:15

Welcome and Introductions

Keith Stewart

Dennis Kim, John Kuruvilla

9:15-10:15

Opening Keynote

Moderators: Dennis Kim, John Kuruvilla

Objectives: After active engagement in this session, participants will be able to:

- describe the foundational principles of TCR discovery and its application in developing targeted immunotherapies for hematologic malignancies;
- evaluate the interplay between cancer biology mechanisms (such as metabolism, genomic instability, and neuroimmunology) and TCR-based therapeutic strategies;
- identify potential challenges and opportunities in integrating multidisciplinary approaches to enhance immunotherapy efficacy in hematologic cancers.

Immunotherapy in Hematology

Tak Mak

10:15-10:45

Refreshment Break

10:45-12:15

Concurrent Sessions

Breakout Session 1

Chronic Myeloid Malignancies and Early Precursor Diseases

Moderator: Vikas Gupta

Objectives: After active engagement in this session, participants will be able to:

- understand the risk of progression of CHIP/CCUS to myeloid malignancies;
- discuss emerging data on role of interferon in ET/PV;
- describe investigational molecular targeted therapies in MPN.

Clonal Hematopoiesis, CCUS and Early MDS

Aniket Bankar

Emerging Role of Interferon in ET and PV
Dawn Maze

CALR Directed Therapies in MPN
Vikas Gupta

10:45-12:15
ILROG Steering
Moderators: Bouthaina Dabaja and Achy Yahalom

12:15-1:45
Lunch/Satellite Symposium

1:45-3:15
Concurrent Sessions

Breakout Session 2
Myeloma
Moderator: Suzanne Trudel

Objectives: After active engagement in this session, participants will be able to:

- discuss the evolving landscape of newly diagnosed multiple myeloma;
- describe how to investigate patients with Monoclonal Gammopathy of Renal Significance (MGRS);
- evaluate the clinical impact of evolving 1st line treatment on sequencing;
- evaluate the clinical impact and practical considerations related to administration of emerging anti-BCMA therapies in early relapse multiple myeloma;
- assess evidence and gaps related to sequencing of anti-BCMA agents with the RRMM treatment algorithm;
- identify treatment paradigms and controversies in the management of MGRS.

Evolving Frontline Strategies for Multiple Myeloma
Guido Lancman

Changing Landscape for 2nd Line Treatment for Relapsed Multiple Myeloma
Suzanne Trudel

Monoclonal Gammopathy of Renal Significance (MGRS) from the Perspective of a Hematologist
Vishal Kukreti

1:45-3:15
Breakout Session 3
Extranodal Lymphomas
Moderator: Badr Id-Said

Objectives: After active engagement in this session, participants will be able to:

- understand the clinical behavior of indolent- and aggressive histology extranodal B-cell lymphomas and how these differ from their nodal counterparts;
- describe the clinical behavior of indolent and aggressive histology extranodal B-cell lymphomas and differentiate these from their nodal counterparts;
- describe the use of novel agents and combined modality therapy in the treatment of cutaneous lymphomas.

T-cell/NK Cases
Tomohiro Aoki

Case-based - Extranodal B-cell Lymphomas
Jillian Gunther

Illustrative Cases of Cutaneous Lymphomas
Richard Hoppe

3:15-3:45
Refreshment Break

3:45-5:15
Concurrent Sessions

Breakout Session 4
Targeted Therapy in Acute Myeloid Leukemia: From Molecular Heterogeneity to Clinical Application
Moderator: Andre Schuh

Objectives: After active engagement in this session, participants will be able to:

- describe the molecular heterogeneity of acute myeloid leukemia;
- review the clinical evidence supporting FLT3 inhibitors in AML;
- evaluate the role of IDH1 and IDH2 inhibitors in AML.

Chemo-immunotherapy in ALL
Maria Agustina Perusini

Targeted Therapy in AML
Andre Schuh

High Risk MDS
Karen Yee

3:45-5:15
Breakout Session 5
Image Guidance/Response Adaptation in Lymphoma
Moderator: Danielle Rodin

Objectives: After active engagement in this session, participants will be able to:

- describe the role of functional imaging in the treatment of Hodgkin and Non-Hodgkin lymphoma in the context of the contemporary systemic therapy regimens;
- recognize sources of false-positive and false-negative PET scans in lymphoma;
- explain emerging concepts in treatment response for lymphoma.

Response Adaptation or Succinct Review of Current Indications for RT in DLBCL
George Mikhaeel

Imaging Dilemmas
Ur Metser

Pet Imaging
Vanessa Murad

Clinical Dilemmas
Abi Vijenthira

6:30
Faculty Dinner
TBD

Friday March 27, 2025

7:30-8:30
Registration and Breakfast

8:30-10:00
Concurrent Sessions

Breakout Session 6
Chronic Lymphocytic Leukemia and Low Grade Lymphoma
Moderator: Lena Specht

Objectives: After active engagement in this session, participants will be able to:

- understand the role of fixed-duration combination regimens and novel BTK inhibitors in the management of chronic lymphocytic leukemia;
- identify which indolent lymphoma patients are suitable for very low-dose radiation therapy and describe the outcome of this treatment;
- understand how to incorporate novel immune therapies (e.g. bispecifics, CAR-T) into the management of follicular lymphoma.

Chronic Lymphocytic Leukemia
Abi Vijenthira

Advanced Stage FL
Robert Kridel

Low dose RT for Indolent NHL
Brandon Imber

8:30-10:00
Breakout Session 7
Delivering Durable Benefit: Allo-HCT for Older Adults, Maintenance, and Long-Term Complications
Moderator: Jonas Mattsson

Objectives: After active engagement in this session, participants will be able to:

- discuss considerations for transplant of elderly and frail patients;
- explain perspective on new ways of reducing relapse post allo-BMT;
- list complications long-term after allo-BMT and best way to manage clinically.

Transplant of Older Patients
Rajat Kumar

Maintenance Therapy Post Allo-BMT
Dennis Kim

Long-term Complication After Allo-BMT
Corey Cutler

10:00-10:30
Refreshment Break

10:30-12:15
CAR T Cell
Moderator: Christine Chen

Objectives: After active engagement in this session, participants will be able to:

- share the status of CAR T-cell therapy in Canada;
- provide guidance on referring and managing patients preparing for CAR T;
- outline highlights and challenges of cell therapy modalities (BMT and CAR T).

The Landscape of CAR T in Canada
Sita Bhella

CAR T Patient Selection and Preparation
Caron Jacobson

Contrasting Cell Therapies: CAR T and AlloBMT
Christine Chen, Ivan Pasic

12:15-1:15
Hodgkin's Lymphoma Session
Moderator: Hans Eich

Objectives: After active engagement in this session, participants will be able to:

- describe the role of combined modality therapy in Early Favourable Classical Hodgkin Lymphoma and identify patients for whom chemotherapy alone may be appropriate;
- identify patients with advanced cHL who are candidates for front-line therapy containing a PD-1 antibody or a chemotherapy regimen including brentuximab vedotin;
- understand the data supporting a second line approach in some patients with relapsed cHL where autologous stem cell transplantation could be omitted.

Illustrative Cases of Hodgkin's Lymphoma
Michael Crump

Illustrative Cases of Early-Stage Stage Hodgkin's Lymphoma
Sarah Milgrom

1:15-2:45
Lunch/Satellite Symposium

2:45-3:45
Oral Abstract Presentations
6 x 10 min

Moderator:

Objectives: After active engagement in this session, participants will be able to:

- describe the latest research conducted in hematologic malignancies;
- discuss opportunities for future research collaborations and proposals.

3:45-5:15

MRD Symposium (Leukemia and LMT)

Moderator: Dennis Kim

Objectives: After active engagement in this session, participants will be able to:

- analyze the impact of intratumoral heterogeneity and chemotherapy response patterns in acute myeloid leukemia (AML);
- evaluate the clinical utility and limitations of current MRD monitoring techniques (flow cytometry and molecular methods) in AML to determine appropriate timing and thresholds for treatment intensification or de-escalation in routine practice;
- select risk-adapted MRD-guided management strategies for patients with aggressive lymphomas during chemotherapy and surveillance settings, incorporating the latest consensus guidelines and prognostic implications.

AML Heterogeneity and Chemo Response

Andy Zeng

AML

Steve Chan

Lymphoma

Robert Kridel

5:15-6:30

Poster Viewing and Reception

March 28, 2025

7:30-8:30

Breakfast / Satellite Symposium

8:30-10 :00

Concurrent Sessions

Breakout Session 8

Aggressive Lymphoma

Moderator:

Objectives: After active engagement in this session, participants will be able to:

- describe the clinical indications for antibody-drug conjugates, radiation therapy, and bispecifics in the management of aggressive histology lymphomas;
- appreciate the clinical circumstances in which regimens other than R-CHOP are appropriate;
- identify options to manage patients with significant comorbidities and how these impact prognosis.

Case-based Discussion

John Kuruvilla

Clinical Dilemmas

Inna Gong

Aggressive Histology Lymphomas

Christopher Kelsey

8:30-10:00

Breakout Session 9

Nursing – Developing Nursing Confidence in Clinical Practice: Fever Management and Shared Care

Moderator: Cindy Murray

Approach to Fever in Malignant Hematology: Infection, CRS, and Beyond

Shea-Lyn Cutmore, Jessica Lois

Objectives: After active engagement in this session, participants will be able to:

- recognize fever early & understand its clinical significance;
- assess, differentiate & triage patients with fever;
- initiate prompt nursing interventions & ongoing monitoring.

Shared Care in the Management of Hematologic Malignancies

Kalique Dzidah, Rosemary Pivovarov

Objectives: After active engagement in this session, participants will be able to:

- describe shared-care models in hematologic malignancies;
- illustrate appropriate division of care using clinical scenarios;
- highlight effective communication & coordination strategies to optimize shared care delivery & continuity of care.

10:00-11:30

Shared Care Model of Non-intensive Treatment for AML Using VEN-AZA Regimen

Moderators: Peter Anglin, Anthony Naassan

Objectives: After active engagement in this session, participants will be able to:

- evaluate the efficacy, safety profile, and patient selection criteria for the venetoclax-azacitidine (VEN-AZA) regimen in newly diagnosed AML patients in outpatient settings;
- implement a shared care model involving collaboration with community hematologists to optimize VEN-AZA administration, monitoring, and supportive care for AML patients in regional healthcare systems;
- compare the treatment outcomes from the Paradigm phase 2 study of VEN-AZA versus 7+3 induction chemotherapy in fit, newly diagnosed AML patients to inform treatment decision-making in clinical practice.

VEN-AZA for AML in the Community

Mitchell Sabloff

Bispecific Antibody Care and Post-CAR T-cell Care in the Community

Sita Bhella

Lymphoma Treatment in the Community

John Kuruvilla

10:00-11:00

ILROG Business Meeting

Moderator:

11:30-12:00

Refreshment Break

12:00-1:15

Leukemia & Lymphoma Society of Canada Research Symposium

The Future of Hematologic Malignancies - From the Lab to the Clinic

Moderator: Aaron Schimmer

Objectives: After active engagement in this session, participants will be able to:

- describe three major recent discoveries in blood cancer pathogenesis and discuss their potential impact on clinical practice of blood cancer patients;
- compare emerging diagnostic technologies and targeted therapies in the Princess Margaret translational pipeline with current standard-of-care approaches;
- identify appropriate patient populations and clinical scenarios in which novel PM-developed diagnostics or therapies could be potentially applied.

What Does Happen in the Bone Marrow of Leukemia Patient Nearby Leukemic Blasts? A model of T-cell ALL and bone marrow microenvironment

Anastasia Tikhonova

Multidimensional Characterization of Tumor–Immune Architecture Reveals Clinically Relevant Classic Hodgkin Lymphoma Subtypes

Tomohiro Aoki

GvHD-Microbiome

Doris Ponce

12:00-1:00

Breakout 10

Pharmacy

Moderator: Melissa Lo

Reactivation of Infections in Immunocompromised Patients

Speakers: Duke Boampong, Ivan Tyono

Objectives: After active engagement in this session, participants will be able to:

- interpret diagnostic strategies for latent infections and early reactivation;
- outline prevention and management strategies, including prophylaxis and treatment protocols.

Nursing Recognition and Management of CRS and ICANS in Patients Treated with Bispecific

Antibodies and CAR-T

Objectives: After active engagement in this session, participants will be able to:

- apply evidence-based nursing interventions for CRS and ICANS;
- demonstrate effective communication and documentation during escalation;
- educate patients and caregivers on warning signs and self-monitoring.

Shared Care in the Management of Hematologic Malignancies

Objectives: After active engagement in this session, participants will be able to:

- discuss communication strategies for multidisciplinary collaboration;
- evaluate best practices for patient transitions between centres;
- formulate recommendations for improving shared care coordination.

1:15-2:15

Closing Keynote

Moderators: Dennis Kim/John Kuruvilla

Objectives: After active engagement in this session, participants will be able to:

- discuss the evolution of the Ontario CMH System over the past decade and shared care implementation;
- discuss future directions in Ontario CMH System for the next 10 years and opportunities for enhancement;
- identify obstacles and strategies to overcome them.

Advancing Complex Malignant Hematology in Ontario: From Evolution to Innovation in Shared Care

Chris Bredeson

2:15-2:25

Closing Remarks